Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Core Viewpoint - Alvotech is set to release its financial results for the full year 2024 on March 26, 2024, and will hold a conference call for analysts on March 27, 2025, indicating ongoing engagement with investors and analysts [1][2]. Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a global leader in the biosimilar space by providing high-quality, cost-effective products [4]. - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), which are marketed in multiple global markets [4]. - Alvotech's development pipeline includes nine disclosed biosimilar candidates targeting various conditions such as autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [4]. Strategic Partnerships - Alvotech has established a network of strategic commercial partnerships to enhance its global reach and leverage local expertise across various regions, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [4]. - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and Dr. Reddy's, among others, each covering unique products and territories [4].